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Objectives: (1) Compare ideal cut-off points for DS and %FEV1 at 1 and 3 h to predict hospital-
ization/relapse in subjects with moderate to severe asthma exacerbation (2) Develop a multi-
variate regression model using DS, %FEV1, demographic, and clinical variables to predict
hospitalization/relapse.
Methods: Subjects with acute exacerbation of asthma (FEV1 <50% predicted following
30 min of standardized treatment: 5 mg nebulized albuterol; 0.5e1.5 mg nebulized ipratro-
pium; and 50 mg oral prednisone) were eligible. All subjects had %FEV1 and DS obtained at
baseline and hourly for 3 h. Using hospitalization/relapse as the outcome of interest; we
compared the area under the receiveroperator curves (AUC) between the 1 and 3 h DS and
%FEV1 measurements, and the AUC for the change in DS and %FEV1 between baseline and
hour-3. We determined ideal cut-points for %FEV1 and DS to maximize sensitivity and speci-
ficity. Sensitivity, specificity, positive and negative predictive values, and positive and nega-
tive likelihood ratios (LR) were compared between %FEV1 and DS. We developed a
multivariate regression model examining the association of specific demographic and clinical
variables to hospitalization/relapse.
Results: 142 patients were included for analysis. The AUC was greatest for the 3-h DS (0.721),
followed by the 3-h %FEV1 (0.669). Optimum cut-off values were a DS of 2, and an FEV1 of 42%.
These were associated with a þLR for the composite outcome of 3.06 and 2.48 respectively.tl.edu (L.M. Lewis).
14.06.006
hts reserved.
DS and %FEV1 are predictors of hospitalization/relapse in patients 1285Logistic regression showed baseline DS, 3-h DS, change in DS, and oxygen use at hour 3 were all
associated with the composite outcome.
Conclusions: The 3-h score for %FEV1 and DS performedbetter than scores at any other time point
and better than either parameter over time. The 3-h DS had the greatest association with the
composite outcome. Neither test was a strong enough predictor to be used solely for this purpose.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Asthma accounts for approximately 1.75 million emergency
department visits per year, leading to approximately 500,000
annual hospitalizations [1,2]. More than $12 billion is spent
on asthma care each year, with hospitalizations accounting
for approximately 20% of these costs [2e4]. Currently, there
are no standardized criteria with which to make the decision
regarding hospitalization for patients with asthma exacer-
bations. Research in both adult and pediatric populations has
shown that historical factors, patient symptoms, and clinical
signs do not accurately predict the need for hospital admis-
sion [5e10]. According to published guidelines of the Na-
tional Asthma Education and Prevention Program (NAEPP)
Expert Panel Report 3, an incomplete response to treatment
(defined as a forced expiratory volume in one second [FEV1]
between 40 and 69%) andmild tomoderate symptoms should
prompt consideration for admission into the hospital. They
further suggest a repeated lung function measure, one hour
after initiation of treatment, to be the strongest single
predictor of hospitalization [11].
Despite these recommendations, studies have shown that
repeated lung functionmeasures are not consistently used to
determineneed for hospitalization. In a previous prospective
study only 43% of patients with an FEV1 <50% at 1 h post-
treatmentwere admitted to the hospital [12]. Anothermulti-
center study found that 51% of patients with a last recorded
FEV1 <50% were discharged home, with a relapse rate (un-
scheduled visit within 72 h) of only 3% [2]. There is little
medical literature supporting %FEV1 as a suitable indicator of
the need for hospitalization. The literature that does exist
often examines %FEV1 as one of many factors in a physician’s
decision for hospital admission or suggests that taken alone,
the %FEV1 cutoff must be lower (40% or 30%) to accurately
predict the need for hospitalization [13,14]. These studies,
as well as others, suggest that the current criteria used to
assess the need for hospitalizationmay lack validity [15]. The
primary objective of this study was to determine if the
change in %AUC in DS or %FEV1 over a 3-h observation period
was a better predictor of hospitalization/relapse than the
static 1-h or 3-h DS or %FEV1 values. In other words, does
improvement in %FEV1 andDS add predictive value to the raw
score alone? Our secondary objective was to identify the
ideal cut-points for DS and %FEV1 at 3-h post-treatment to
predict the composite endpoint of hospitalization on the
index visit or relapse within 7 days, among selected emer-
gency department subjects with moderate to severe asthma
exacerbation. We also compare the sensitivity, specificity,
positive, and negative predictive values, and positive and
negative likelihood ratios between the ideal %FEV1 and DS
values as determined by the ROC.Finally we developed a multivariate logistic regression
model using a combination of DS and %FEV1 along with
specific demographic and clinical variables to determine
which, if any, variables are associated with an increase or
reduction in the odds of the primary outcome; hospitali-
zation/relapse.Methods
Study design
This is a secondary analysis of a prospective, multi-center,
phase 2 double-blind, randomized controlled interventional
trial, comparing an intravenous b2 adrenergic agonist and
standard therapy to standard therapy alone in the ED man-
agement of acute exacerbation of asthma (clinicaltrials.gov
identifier NCT00838591). The study was approved by the
institutional review boards at all participating sites, and the
Washington University Human Research Protection Office.
Study setting and population
The study setting included nine academic adult EDs in the
United States enrolling participants from January 15, 2009 to
March 15, 2012. Study coordinators, experienced in per-
forming clinical trials, and who received specific training for
this trial, enrolled subjects between 8AM and 10PM on
weekdays, and every other week-end. The complete selec-
tion criteria for the clinical trial can be seen in the Appendix.
Subjects were eligible only if they had an FEV1 <50% of
predicted after receiving initial therapy consisting of al-
buterol (5e15 mg nebulized), inhaled ipratropium
(0.5e1.5 mg), and at least 50 mg of oral prednisone or its
equivalent, all within a 2-h time window. All subjects that
were randomized in the interventional trial were included
in this secondary analysis, as long as they had %FEV1 and DS
documented, whether or not they received active drug or
placebo, because we felt this should not affect the asso-
ciation between %FEV1 or DS and hospitalization or relapse.
A CONSORT flow diagram of the trial can be seen in Fig. 1.
The clinical trial sought 200 subjects to have adequate
power for their primary endpoint.
Study protocol
Eligible subjects were to have serial %FEV1 and Modified
Borg Dyspnea Score (Table 1) measured at baseline and
hourly, for three hours. Baseline was defined as just prior to
administration of either study drug or placebo.
Figure 1 Consort flow diagram for sub-study.
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Following randomization, subjects were assigned to receive
either a 1-h infusion of study drug or placebo. Subjects andTable 1 The modified Borg dyspnea scale.
Modified Borg scale
Scale Severity (difficulty breathing)
0 No difficulty breathing
0.5 Very, very mild (Just Noticeable)
1 Very mild (noticeable but not bothersome)
2 Mild (slightly bothersome)
3 Moderate
4 Somewhat severe
5 Severe
6
7 Very severe
8
9 Very, very severe (almost maximal)
10 Maximal difficulty breathing
The Modified Borg Dyspnea Scale is a 0e10 point scale with
corresponding descriptors regarding the patient’s perceived
difficulty breathing. Patients are asked to circle the number
that best corresponds to their severity of symptoms (From
Burdon JGW, Juniper EF, Killian KJ, Hargrave FE, Campbell EJM.
The perception of breathlessness in asthma. Am Rev Respir Dis
1982;126:825e8. Official Journal of the American Thoracic So-
ciety, with modifications from Kendrick KR, Baxi SC, Smith RM.
Usefulness of a modified 0e10 point Borg scale in assessing the
degree of dyspnea in patients with COPD and asthma. J Emerg
Nursing 2000; 26:216e22, Kendrick et al., 2000).their treating physicians were blinded as to whether they
were in the treatment or placebo arm. During the study
treatment period, all subjects continued to receive standard
asthma therapy as needed, based on the clinical judgment of
the treating physician. The final decision regarding hospi-
talization or discharge did not involve the asthma study
team, and was made solely by the emergency physicians
primarily responsible for treating the patient. The treating
physicians did not have access to the study %FEV1 or DS re-
sults. The study teamdid not inquire into the specific reasons
for the disposition decision. Although study spirometry and
DS results were not available to the treating physicians, they
could independently order or perform spirometry if desired.
The most common form of spirometry used in this setting, at
most of the participating sites, was bedside peak expiratory
flow rate. We were unable to determine how often, if ever,
this was used for disposition decision-making. The Modified
Borg Dyspnea Score was not routinely used for disposition
decision-making in patients with acute asthma exacerbation
at the participating study sites.
Data collection
Demographic (age, race, gender, smoking history) and
clinical data including respiratory rate, use of supplemental
oxygen, dyspnea score, and %FEV1 were obtained on pre-
sentation. A Health Status Assessment was performed at
baseline and hourly for 3 h. This assessment included vital
signs, respiratory examination, spirometry, and dyspnea
score. Spirometry (%FEV1) using an nSpire spirometer
(nSpire Health, Inc. Longmont, CO) was performed 3 times
in succession with the best effort recorded. Assessment of
dyspnea was recorded using the Modified Borg Dyspnea
Scale [16,17]. Several authors have validated this scale
both in asthma and chronic obstructive pulmonary disease
(COPD) [18e21]. Outcomes included hospitalization on the
index visit or relapse within 7 days, admission to an inten-
sive care unit, and mean length of stay. Subjects discharged
home on their index visit, had follow-up at 24 h and at 8  1
days to determine if they had an unscheduled visit to any
healthcare provider for worsening asthma (relapse). Data
was entered into a database file using Microsoft Excel 2010
(Microsoft Corporation, Redmond, WA).
Statistical analysis
We report the following descriptive statistics for our study
population: median age (IQR), race, gender, smoking status,
admission rate, ICU admission rate, mean length of stay, and
mean (SD) %FEV1 and DS at baseline and at 1, 2, and 3 h post
baseline (Table 2). The composite outcome was defined as
hospitalization on the index visit or relapse within 7 days.
Receivereoperator curves were generated for DS and %
FEV1 at all 4 time points (baseline, 1, 2, and 3 h post base-
line). ROC curves were also generated for the change in both
DS and %FEV1 over time (baseline to 3 h post-baseline). C-
statisticswere used to choose the optimumtimepoint for the
logistic regression model for each parameter. Following
univariate analysis, a multivariate logistic regression anal-
ysiswas performed. TheHosmereLemeshow testwas used to
test goodness of fit. We performed sensitivity, specificity,
Table 2 Demographic and clinical characteristics of the study population.
Hospitalized/relapsed Discharged N P-value
Demographics Median (IQR) Median (IQR)
Age 38 (28e44) 35 (25e44) 137
Frequency (%) Frequency (%)
Sex 161
Male 28 (17) 46 (29)
Female 45 (28) 42 (26)
Race
African-American 46 59
Caucasian 23 25
Other 4 4
Clinical characteristics
Current Smoker 32 (20) 20 (12) 161
Mean (STD) Mean (STD)
Admitted to ICU 4 (2.8) 142
Length of ICU Stay 2.45 (1.61)
Baseline %FEV1 33.9 (10.3) 39.2 (9.8)
Baseline DS 5.3 (2.5) 4 (2.4)
Hr. 1 %FEV1 35.9 (12.6) 44.2 (11.7) <0.001
Hr. 1 DS 3.5 (2.2) 2.9 (2.1)
Hr. 2 %FEV1 38.1 (13.5) 46.8 (13.2)
Hr. 2 DS 3.5 (2.3) 1.9 (1.7)
Hr. 3 %FEV1 40.1 (15.3) 49.2 (12.4) <0.001
Hr.3 DS 3.2 (2.3) 1.5 (1.6)
%FEV1 is the percent of total expiratory volume in one second, predicted based on age, gender, height, and weight.
DS is the Modified Borg Dyspnea Scale score which ranges from 0 to 10, with 0 being no dyspnea, and 10 being maximal dyspnea.
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(PPV), and likelihood ratios (LR) for the 3-h %FEV1 and 3-h DS
using the ROC to determine the single best cut-off point (to
maximize sensitivity and specificity). Data were analyzed
using SAS version 9.3 (Cary, NC).Results
There were 175 subjects enrolled in the phase II trial, with
161 completing the study. Sixty-five subjects (37.1%) were
hospitalized on their index visit, and another 11 (6.3%)
relapsed and required unscheduled carewithin the follow-up
period. We had complete DS data on 159 of these subjects,
and complete spirometric data on 142. Specific demographic
and clinical data on our subjects can be seen in Table 2. Of
the 142 subjects with complete DS and spirometric data, 59
(41.5%) were hospitalized on their index visit, and an addi-
tional 7 subjects (4.9%) relapsed within the 7-day follow-up
period. The average length of stay (LOS) for admitted sub-
jects was 2.45 days. The mean 3-h %FEV1 for hospitalized/
relapsed subjects was 39.3 vs. 49.3 for discharged subjects
who did not relapse; (p< 0.001). The often recommended 3-
h %FEV1 cut-off of 50% had fairly good sensitivity with 47 of 59
(79.7%) hospitalized/relapsed subjects having an hour-3
FEV1 <50%. However, it had poor specificity, with 44 of 78
(56.4%) discharged patients also having an hour-3 FEV1<50%.
The calculated area under the receivereoperator curve
was greatest for the hour-3 DS, followed by the hour 3%FEV1
(Table 3, Fig. 2). The hour-3 DS and the hour-3%FEV1 logistic
regression models had the largest c-statistic of all time
points considered and also had a larger c-statistic than thepercentage change over time (baseline to hour 3) in DS or %
FEV1 (Table 3, Fig. 2) and so were the only time points
considered in the multivariate analysis.
Race, gender, age, baseline %FEV1 and smoking history
(current smoker vs. not current smoker) were not signifi-
cant predictors of hospitalization/relapse in univariate
analysis. The final multivariate model included DS, %FEV1,
oxygen use at hour-3, and respiratory rate at hour-3. The
model shows the odds of hospitalization/relapse for each
incremental unit change in %FEV1 or DS (Table 4) This
multivariate model has c statistics of 0.759 and a Hos-
mereLemeshow test result of 6.43 (df Z 8; P Z 0.5994),
indicating that the model including the combination of DS
and %FEV1 has a good fit to the data.
Based on the ROC curves, the ideal cut-off point to
maximize sensitivity and specificity for our composite
outcome for FEV1 was 42% and for dyspnea was a score of 2.
Sensitivity, specificity, PPV, NPV, and LR using these cut-off
points can be seen in Table 5. The 2  2 tables can be seen
in the Appendix.Discussion
Developing objective criteria to accurately determine need
for hospitalization in patients with asthma exacerbation
has proven elusive. There have been numerous studies over
the past 3-4 decades that have attempted to develop
clinical indices using a variety of clinical parameters, and
pulmonary function studies to predict the need for hospi-
talization in acute exacerbations of asthma [5e10,22e24].
Some of these indices often required several objective
Table 3 Area under the curve and predicted probabilities for %FEV1 and DS at baseline, 1 h, 3 h, and change from baseline
to 3 h.
%FEV1 %FEV1 %FEV1 D FEV1 DS DS DS D DS
BL 1 h 3 h BL to 3-h BL 1 h 3 h BL to 3-h
AUC 0.614 0.666 0.669 0.607 0.643 0.676 0.721 0.540
Pred prob %FEV1 Z 25 %FEV1 Z 25 %FEV1 Z 25 DFEV1 0 Z 25% 0 Z 26% 0 Z 26% D Z 0; prob 52%
Prob Z 58% Prob Z 63% Prob Z 65% 10 ml Z 60% 8 Z 66% 8 Z 81% 8 Z 93% D Z 4; prob 45%
%FEV1 Z 50
a %FEV1 Z 60 %FEV1 Z 60 +20 ml Z 32% D Z 4; prob 60%
Prob Z 34% Prob Z 27% Prob Z 32%
%FEV1 is the percent predicted of the forced expiratory volume in one second.
DS is the modified Borg dyspnea score.
BL is at baseline, the D FEV1 is the change in FEV1 (in milliliters) from baseline to the 3 h measurement, the D DS is the change in dyspnea
score from baseline to the 3 h measurement.
AUC is the area under the receiver operating curve.
Pred prob is the predicted probability of hospitalization/relapse at the different cut points shown.
For example an hour-3 DS of “0” is associated with a 26% probability of hospitalization/relapse, whereas an hour-3 DS of 8 is associated
with a 93% probability of hospitalization/relapse.
a By inclusion criteria, no one could have a baseline %FEV1 above 50.
1288 J.E. Schneider et al.factors to be considered, but were still difficult to repro-
duce [25]. Expert consensus opinion suggests the use of
pulmonary function testing (%FEV1 or peak flow) to aid in
clinical decision making regarding the need for hospitali-
zation [11]. These are relatively simple to perform, are an
objective assessment of airflow, and have been extensively
studied. However, the exact cut-off value for these tests to
optimize sensitivity and specificity for the need for hospi-
talization has been debated [2,14,27] and ranges from
<50% predicted to <25% predicted. Perhaps as a result of
this wide variation in a “safe for discharge” %FEV1 its use
for disposition decision making is not widespread. A previ-
ous study showed that emergency physicians reported only
moderate compliance with peak flow testing, with a third
saying they “usually” use pulmonary function testing in
disposition decision making, but only 16% saying they “al-
ways” do so [26]. In several studies in which peak flow or %
FEV1 was performed as part of a study protocol, there was
no significant difference in either initial or subsequent
performance between those that were discharged suc-
cessfully, and those hospitalized or relapsed [5,28,29].
There are fewer published studies on the use of dyspnea
scores in predicting outcome in asthma exacerbation [9].
The Modified Borg Dyspnea Scale has its proponents
[18e21] and detractors [30,31]. Ease of administration and
some degree of validation favor its use. DS is obviously
more subjective than %FEV1, and is thus less alluring.
However, it may be less affected by a patient’s baseline
pulmonary function, and provides complementary
information.
Our study is unique in several ways. It compares %FEV1
head to head with a well described and previously validated
dyspnea scale. Further, it was prospective and adhered to a
tight protocol, with 4 separate assessments (baseline, and
at hour 1, 2, and 3 post-baseline) allowing us to look at both
raw scores at each time point as well as change over time.
Finally, most of the previous studies took place several
decades ago, and there have been significant changes in the
emergency management of asthma during that time,
including the widespread use of observation units, therebypotentially altering the thresholds for %FEV1 and DS that
may trigger hospitalization.
It would seem that improvement, or lack thereof, over
time as reflected in the %FEV1 and DS, would be a better
predictor of subsequent hospitalization or relapse than the
final (3-h) %FEV1 or DS; but this was not the case. To be
sure, change in DS and %FEV1were additional predictors,
but with a lower AUC than the static 3-h values. It may be
that when deciding on patient disposition (hospitalization
or discharge) there is a threshold value (either as measured
or as determined by our clinical gestalt) that is more
important in decision making than the amount of
improvement. For example, patients who may be close to
being “safe for discharge” might only require a small
improvement to be sent home, whereas those who are
severely impaired might improve significantly, and still not
be judged “safe for discharge”. We found DS, particularly
at 3 h post-treatment, to be more reliable than %FEV1 at
any time point, for predicting hospitalization/relapse. The
3-h DS also performed better than the change in either DS
or %FEV1. The logistic regression model found that DS at
3 h and supplemental oxygen use at 3 h were significant
predictors of hospitalization/relapse (with the 3-h %FEV1
narrowly missing significance). The optimum cut-off points
were determined to be 42% for FEV1 and a score of 2 on the
modified Borg dyspnea scale. The þLR for an FEV1 <42% was
2.48, and the þLR for a DS >2 was 3.06. Choosing more
extreme cut-points will alter the LR, but besides being
arbitrary, the more extreme the cut-off point, the less
likely that any clinician would need the test result to aid in
decision making. It appears from the test characteristics
that neither %FEV1 nor DS are reliable enough as predictors
of hospitalization/relapse to be confidently used as the sole
factors for this decision.Limitations
There were several limitations to this study. Although it was
a fairly large multi-center study, the majority of subjects
Figure 2 Dyspnea score and %FEV1 receivereoperating curves. Receivereoperator curves for baseline and hour-3 dyspnea score
(DS), baseline and hour-3 %FEV1, and the change from baseline to hour-3 in both DS and % FEV1. The hour-3 DS has the largest AUC,
followed by the hour-3 %FEV1.
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Table 4 Logistic regression analysis for baseline and
3-h DS, change in DS, and 3-h %FEV1, respiratory rate and
supplemental oxygen use.
Variable OR 95% CI P value
% FEV1 hour-3 0.974 0.947e1.002 P Z 0.07
DS hour-3 1.492 1.196e1.860 P < 0.01
RR at hour 3 1.012 0.907e1.129 P Z 0.83
O2 use at hour 3
(no vs yes)
0.383 0.153e0.960 P Z 0.04
The estimated change in the odds of hospitalization/relapse for
a 1% increase in the hr-3 FEV1 is 0.974 (95%CI; 0.947, 1.002).
Estimated change in odds of hospitalization/relapse for a one
unit increase in 3-h DS is 1.49 (95%CI; 1.20e1.86).
The odds of hospitalization/relapse for not using oxygen at
hour-3 is estimated to be 0.383 times the odds of hospitaliza-
tion/relapse for using oxygen (95%CI; 0.153, 0.960).
1290 J.E. Schneider et al.were enrolled in urban hospitals, and this may affect
generalizability. This study excluded early responders to
therapy, and thus selected for patients with more severe
and refractory asthma exacerbations. Also, %FEV1 was
calculated and reported as percent predicted, and many of
these subjects by virtue of the severity of their asthma may
have remodeling and a “personal best” %FEV1 significantly
lower than predicted. The clinicians making the decision to
admit or discharge our study subjects did not have access to
the study data, and it is unknown whether they based their
decision on spirometry, subjective dyspnea, or other pa-
tient or social factors. As noted previously, repeated
spirometry for disposition decision making was not
frequently used in the study sites prior to the initiation of
this study. Finally, the treatment and emergency manage-
ment of asthma has changed significantly over the past few
decades, including the more widespread use of observation
areas, and may have altered the thresholds for %FEV1 and
DS at which patients are hospitalized.Table 5 Test characteristics for hour-3 %FEV1 <42% and
DS >2.
3-Hour FEV<42% (95% CI)
Sensitivity 57.8% (0.46e0.70)
Specificity 76.7% (0.67e0.86)
Positive predictive value (PPV) 68.5% (0.56e0.81)
Negative predictive value (NPV) 67.5% (0.57e0.78)
Positive likelihood ratio (LR) 2.48 (1.32e3.65)
Negative likelihood ratio (LR) 0.55 (0.34e0.88)
3-Hour DS ‡2 (95% CI)
Sensitivity 55.3% (0.44e0.66)
Specificity 81.9% (0.74e0.90)
Positive predictive value (PPV) 73.7% (0.62e0.85)
Negative predictive value (NPV) 66.7% (0.57e0.76)
Positive likelihood ratio (LR) 3.05 (1.51e4.60)
Negative likelihood ratio (LR) 0.55 (0.40e0.69)
%FEV1 is the percent of total expiratory volume in one second,
predicted based on age, gender, height, and weight.
DS is the Modified Borg Dyspnea Scale score which ranges from
0 to 10, with 0 being no dyspnea, and 10 being maximal
dyspnea.Conclusion
A 3-h FEV1 <42%, or 3-h DS >2 was significantly associated
with hospitalization or relapse; more so than was change in
these measurements over time. Neither test discriminated
accurately enough between subjects who were ultimately
hospitalized or relapsed and those that could be safely
discharged home, to be used as a sole predictor for this
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